Lung cancer is the most commonly diagnosed cancer worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer seriously affect the patients' quality of life and prognosis. The management of MPE includes thoracentesis, pleurodesis, indwelling pleural catheters and drug perfusion in pleural cavity. Vascular endothelial growth factor (VEGF) and its receptor are a group of important ligands and receptors that affect angiogenesis. They are the main factors controlling angiogenesis, and they play an important role in the formation of MPE. Bevacizumab is a recombinant humanized VEGF monoclonal antibody, competitively binding to endogenous VEGF receptor. Bevacizumab can inhibit new blood vessel formation, reduce vascular permeability, prevent pleural effusion accumulation and slow the growth of cancers. This review aims to discuss the progress of bevacizumab in the treatment of MPE caused by non-small cell lung cancer (NSCLC), and explore the clinical application, efficacy, safety and future direction of bevacizumab. .
【中文题目：贝伐珠单抗治疗非小细胞肺癌所致恶性胸腔积液的研究进展】 【中文摘要：肺癌是全球范围内发病率最高的恶性肿瘤，晚期肺癌所致的恶性胸腔积液（malignant pleural effusion, MPE）严重影响患者的生活质量和预后。MPE的治疗手段包括胸腔穿刺术、胸膜固定术、胸腔埋管引流、胸腔内灌注治疗等。血管内皮生长因子（vascular endothelial growth factor, VEGF）及其受体是一组影响血管生成的重要配体和受体，是控制血管生成的主要因素，在MPE的形成中发挥重要作用。贝伐珠单抗是一种重组的人源化VEGF单克隆抗体，可与内源性VEGF竞争性结合VEGF受体，抑制新血管生成以及降低血管通透性，阻碍胸腔积液形成，延缓肿瘤发展进程。本综述旨在讨论贝伐珠单抗治疗非小细胞肺癌所致恶性胸腔积液的研究进展，探讨贝伐珠单抗临床应用的方法、疗效、安全性以及未来的发展方向。 】 【中文关键词：贝伐珠单抗；肺肿瘤；恶性胸腔积液】.
Keywords: Bevacizumab; Lung neoplasms; Malignant pleural effusion.